Peptide Oral Dissolving Film · B2B
Dietary-Grade Peptide Oral Strips
Compliant ingredient screening, custom flavor, film parameters and private-label packaging.
Content updated · Evidence and updates
Immune-wellness positioning requires review of the ingredient and permitted claims for the destination. A film prototype is not evidence of disease prevention.
Begin a dietary oral strip project by identifying the ingredient source, intended use and destination market. The word peptide does not establish that a material is permitted in every supplement category, and a film format does not change the evidence needed for the ingredient or proposed claim. Separate technical development from the decision to place a finished product on a particular market. The formulation brief should state the target amount per strip and the planned number of strips per serving. Compare those figures with the ingredient information that supports the intended positioning. If the desired serving cannot be delivered in a practical film, revise the concept rather than assuming a smaller amount is equivalent. Agree the finished specification, labeling responsibilities and documentation requirements before artwork is finalized. Market review and analytical confirmation should remain linked to the exact commercial formulation.
Film feasibility depends on the complete ingredient specification and the required finished format, not the ingredient name alone. Start with identity, composition, source, target loading and any available analytical method. The development team then evaluates how the material behaves in a proposed polymer system during mixing, casting, drying and storage. A visually acceptable film is only one observation: the sample must also be assessed against agreed analytical and handling requirements. Separate the desired amount per strip from the amount demonstrated in a tested prototype. Film area, dry mass and composition should be reported together so the loading calculation can be checked. A formula change, including a new flavor or sweetener, may require another comparison round. The feasibility outcome should record the version tested, unresolved questions and conditions needed before a pilot decision.
Review the listed combinations and source codes alongside the existing project scope. A catalog reference does not change the ingredient specification, target population or claims permitted for a final product.
The brochure groups vitamin C with zinc, beta-glucan, curcumin, coenzyme Q10, omega-3, magnesium, allicin, milk thistle and several ginseng directions together. A further combination lists kudzu root, Hovenia dulcis fruit and curcumin. Ingredient-based labels below replace unsupported disease or recovery promises. Each entry needs a separate assessment of ingredient identity, permitted use and the desired serving in the destination market. Confirm the proposed loading against film size and handling requirements, then evaluate a documented prototype. No finished-product dosage, shelf life, absorption result or commercial availability is established by this catalog. The listed combinations should not be used as consumer treatment advice. Agree labeling responsibilities and the evidence needed for any proposed statement before commercial artwork is approved. Refer to the original brochure codes when requesting a sample or discussing an alternative ingredient combination.
| Brochure code | Ingredient direction |
|---|---|
| D1 | Vitamin C + Zinc |
| D2 | Beta-glucan |
| D3 | Curcumin |
| D4 | Coenzyme Q10 |
| D5 | EPA/DHA |
| D6 | Magnesium |
| D7 | Allicin |
| D8 | Silymarin |
| D9 | Red ginseng extract |
| D10 | American ginseng extract |
| D11 | Ginseng extract |
| D12 | Kudzu root extract + Hovenia dulcis fruit extract + Curcumin |